DSGN
Design Therapeutics, Inc.
$10.97
+4.18%
$685.2M
No data for this timeframe.
Vol
Market Cap$685.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$219.2M
Inst. Activity10 buys / 4 sells
SEC Reports4
Press Releases2
Recent Activity
Jun 9, 2026
Insider
Berger Heather A. was granted 30,000 shares
Director
Jun 9, 2026
Insider
Gover Justin D. was granted 30,000 shares
Director
Jun 9, 2026
Insider
Shapiro David was granted 30,000 shares
Director
May 21, 2026
short_volume
Short Volume: DSGN — 61.1% short (0.3M / 0.6M)
Short: 342,898 | Exempt: 0 | TRF Vol: 560,799 | Short Ratio: 61.1% | Off-exchange volume (dark pool
May 18, 2026
SEC
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial of DT-216P2 in Fr
8-K — Impact 7/10
May 18, 2026
Press
Design Therapeutics announced positive Phase 1/2 RESTORE-FA data for DT-216P2 in Friedreich ataxia, showing dose-depende
Impact 8/10
Apr 28, 2026
SEC
Design Therapeutics reported Q1 2026 net loss per share of $(0.29), beating consensus of $(0.33) by 12%. The company hig
PRESS-RELEASE — Impact 5/10
Apr 23, 2026
SEC
Design Therapeutics is holding its annual shareholder meeting on June 9, 2026, to vote on electing one Class II director
DEFA14A — Impact 3/10
Price Targets
$21.00
+91.4% upside
Strong Buy
Current $10.97
Low $20.00
Median $21.00
High $22.00
6 analysts
$20.00
$22.00
Analyst Ratings
5Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Mar 16, 2026 | Jefferies | INITIATE | Buy |
| Mar 10, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Jan 7, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.34 ▲ +3.8% | $-0.46 — $-0.29 | -1% YoY | 7 |
| Next Q | $-0.36 ▲ +0.9% | $-0.38 — $-0.29 | -20% YoY | 7 |
| Current FY | $-1.36 ▲ +3.1% | $-1.63 — $-1.17 | -11% YoY | 7 |
| Next FY | $-1.64 ▲ +4.6% | $-2.04 — $-1.35 | -20% YoY | 7 |
Latest Reports
BULLISH
8-K
7/10
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial of DT-216P2 in Fr
May 18, 2026
BULLISH
Press
8/10
Design Therapeutics announced positive Phase 1/2 RESTORE-FA data for DT-216P2 in Friedreich ataxia, showing dose-depende
May 18, 2026
BULLISH
PRESS-RELEASE
5/10
Design Therapeutics reported Q1 2026 net loss per share of $(0.29), beating consensus of $(0.33) by 12%. The company hig
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $31.6M | DOUBLED |
| Point72 Asset Management, L.P. | $29.0M | TRIM |
| BAKER BROS. ADVISORS LP | $27.5M | ADD |
| BlackRock, Inc. | $22.7M | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $18.6M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Berger Heather | A | $0.00 |
| Jun 9, 2026 | Gover Justin | A | $0.00 |
| Jun 9, 2026 | Shapiro David | A | $0.00 |
| Jun 9, 2026 | LAPPE RODNEY | A | $0.00 |
| Jun 9, 2026 | Schmid John | A | $0.00 |
50 institutional holders with $219.2M total value (20,611,690 shares) as of 2026-Q1. Top holders: RA, Point72, BAKER. Net buying activity: 10 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 2,972,973 | $31.6M | 14.4% | DOUBLED +103.4% |
| 2 | Point72 Asset Management, L.P. | 2,722,754 | $29.0M | 13.2% | TRIM -49.3% |
| 3 | BAKER BROS. ADVISORS LP | 2,585,978 | $27.5M | 12.5% | ADD +30.4% |
| 4 | BlackRock, Inc. | 2,133,764 | $22.7M | 10.4% | — |
| 5 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,744,987 | $18.6M | 8.5% | ADD +47.9% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,349,850 | $14.4M | 6.6% | — |
| 7 | Woodline Partners LP | 961,501 | $10.2M | 4.7% | ADD +54.1% |
| 8 | FMR LLC | 798,411 | $8.5M | 3.9% | — |
| 9 | STATE STREET CORP | 659,575 | $7.0M | 3.2% | — |
| 10 | MORGAN STANLEY | 656,565 | $7.0M | 3.2% | DOUBLED +299.1% |
| 11 | GOLDMAN SACHS GROUP INC | 504,718 | $5.4M | 2.4% | — |
| 12 | D. E. Shaw & Co., Inc. | 470,270 | $5.0M | 2.3% | — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 431,840 | $4.6M | 2.1% | ADD +45.0% |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 408,200 | $4.3M | 2.0% | ADD +42.2% |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 241,485 | $2.6M | 1.2% | — |
| 16 | CITADEL ADVISORS LLC | 231,513 | $2.5M | 1.1% | TRIM -34.1% |
| 17 | VANGUARD FIDUCIARY TRUST CO | 195,658 | $2.1M | 0.9% | — |
| 18 | MARSHALL WACE, LLP | 151,008 | $1.6M | 0.7% | TRIM -33.0% |
| 19 | Invesco Ltd. | 141,920 | $1.5M | 0.7% | TRIM -53.6% |
| 20 | VANGUARD PORTFOLIO MANAGEMENT LLC | 138,565 | $1.5M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | DOUBLED | 1,461,381 | 2,972,973 | +103.4% | $31.6M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 5,372,004 | 2,722,754 | -49.3% | $29.0M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 1,179,817 | 1,744,987 | +47.9% | $18.6M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 297,921 | 431,840 | +45.0% | $4.6M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 287,100 | 408,200 | +42.2% | $4.3M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 225,528 | 151,008 | -33.0% | $1.6M | 2026-Q1 |
| Invesco Ltd. | TRIM | 305,757 | 141,920 | -53.6% | $1.5M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 52,730 | 133,203 | +152.6% | $1.4M | 2026-Q1 |
| STRS OHIO | ADD | 25,200 | 44,700 | +77.4% | $475.6K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | NEAR_EXIT | 158,383 | 34,990 | -77.9% | $372.3K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 15,541 | 20,644 | +32.8% | $219.7K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | ADD | 11,824 | 14,824 | +25.4% | $157.7K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 738 | 3,684 | +399.2% | $39.2K | 2026-Q1 |
| CWM, LLC | ADD | 239 | 423 | +77.0% | $4.5K | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 3,340,552 | 5,372,004 | +60.8% | $50.4M | 2025-Q4 |
| BAKER BROS. ADVISORS LP | ADD | 1,712,882 | 2,233,099 | +30.4% | $20.9M | 2025-Q4 |
| RA CAPITAL MANAGEMENT, L.P. | DOUBLED | 475,699 | 1,461,381 | +207.2% | $13.7M | 2025-Q4 |
| Woodline Partners LP | ADD | 612,712 | 944,039 | +54.1% | $8.9M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 175,991 | 702,306 | +299.1% | $6.6M | 2025-Q4 |
| Invesco Ltd. | DOUBLED | 14,589 | 305,757 | +1995.8% | $2.9M | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 27,062 | 50,657 | +87.2% | $475.2K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 18,317 | 26,786 | +46.2% | $251.3K | 2025-Q4 |
| Russell Investments Group, Ltd. | DOUBLED | 6,377 | 25,234 | +295.7% | $236.7K | 2025-Q4 |
| MetLife Investment Management, LLC | ADD | 10,320 | 15,249 | +47.8% | $143.0K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 2,202 | 2,768 | +25.7% | $26.0K | 2025-Q4 |
6 unique insiders with 7 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Berger Heather A. | Director | AWARD | 30,000 | — | — |
| Jun 9, 2026 | Gover Justin D. | Director | AWARD | 30,000 | — | — |
| Jun 9, 2026 | Shapiro David | Director | AWARD | 30,000 | — | — |
| Jun 9, 2026 | LAPPE RODNEY W | Director | AWARD | 30,000 | — | — |
| Jun 9, 2026 | Schmid John P. | Director | AWARD | 30,000 | — | — |
| Jun 9, 2026 | George Simeon | Director | AWARD | 30,000 | — | — |
| Mar 31, 2026 | Shapiro David | Director | AWARD | 60,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
BULLISH
8-K
7/10
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA tri
May 18, 2026
BULLISH
PRESS-RELEASE
5/10
Design Therapeutics reported Q1 2026 net loss per share of $(0.29), beating consensus of $(0.33) by
Apr 28, 2026
NEUTRAL
DEFA14A
3/10
Design Therapeutics is holding its annual shareholder meeting on June 9, 2026, to vote on electing o
Apr 23, 2026
NEUTRAL
3
2/10
David Shapiro, a director or 10% owner of Design Therapeutics, Inc., filed a Form 3 to report his in
Apr 1, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 5 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$21.00 mean target
+91.4% upside
Strong Buy (1.29)
$20.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $10.97 |
| Target Low | $20.00 |
| Target Mean | $21.00 |
| Target Median | $21.00 |
| Target High | $22.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.34 | $-0.46 | $-0.29 | -1.3% | +3.8% | 3↑ 1↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.36 | $-0.38 | $-0.29 | -19.5% | +0.9% | 3↑ 0↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-1.36 | $-1.63 | $-1.17 | -11.5% | +3.1% | 3↑ 2↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-1.64 | $-2.04 | $-1.35 | -20.3% | +4.6% | 3↑ 2↓ | $0.0B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.344 | |
| 7d ago | $-0.344 | |
| 30d ago | $-0.358 | +0.014 |
| 60d ago | $-0.358 | +0.014 |
| 90d ago | $-0.352 | +0.008 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 16, 2026 | Jefferies | INITIATE | — | Buy |
| Mar 10, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 7, 2026 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
short_volume
Short Volume: DSGN — 61.1% short (0.3M / 0.6M)
Short: 342,898 | Exempt: 0 | TRF Vol: 560,799 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
fda
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
<p align="center"><em>DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and pro
May 17, 2026
fda
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
<p align="left">CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company
May 5, 2026
earnings_calendar
DSGN Q1 2026 Earnings Scheduled — 2026-05-05
Apr 28, 2026
earnings
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
<p align="center"><em>Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints</em></p>
Mar 17, 2026
earnings_calendar
DSGN Q4 2025 Earnings After Market Close — 2026-03-17
Mar 9, 2026
earnings
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
<p align="center"><em>Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026</
Mar 9, 2026
earnings_calendar
DSGN Q4 2025 Earnings After Market Close — 2026-03-09